muraglitazar

Subscribe to Selected New Research on muraglitazar

15 relevant articles (0 outcomes, 1 trials/studies) found for this Bio-Agent

Description: has glucose- and lipid-lowering activities; structure in first source; molecule composed of benzyloxazole-phenoxy-oxybenzylglycine-phenoxyl having structural analogy to PHENOXYBENZAMINE

Also Known As:

BMS 298585; BMS-298585; BMS298585; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; Pargluva; 2-((4-methoxyphenoxy)carbonyl-((4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy)phenyl)methyl)amino)acetic acid

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Azoles: 224

Oxazoles: 1

muraglitazar: 15

Amino Acids, Peptides, and Proteins

Amino Acids: 8523

Glycine: 2859

muraglitazar: 15

Experts

1.	Liebson, Philip R: 1 article (01/2006)
2.	Lee, Patrick Y: 1 article (01/2006)
3.	Moehlenkamp, Jeffrey D: 1 article (01/2006)
4.	Waites, Crystal R: 1 article (01/2006)
5.	Van Vleet, Terry: 1 article (01/2006)
6.	Arnold, Lora E: 1 article (01/2006)
7.	White, Melvin R: 1 article (01/2006)
8.	Tannehill-Gregg, Sarah: 1 article (01/2006)
9.	Yun, Anthony J: 1 article (01/2006)
10.	Dominick, Mark A: 1 article (01/2006)

Related Diseases

1.	Edema 05/01/2006 - "Weight gain and edema were more common when muraglitazar was compared with a submaximal dose of pioglitazone." 05/01/2006 - "At week 24, weight gain (1.4 and 0.6 kg, respectively) and edema (9.2 and 7.2%, respectively) were observed in the muraglitazar and pioglitazone groups; at week 50, weight gain and edema were 2.5 and 1.5 kg, respectively, and 11.8 and 8.9%, respectively" 10/01/2008 - "To investigate the mechanistic basis underlying this adverse event, we performed a candidate gene analysis of patients enrolled in clinical trials of muraglitazar, an investigational PPARalpha/gamma dual agonist, and developed a cell culture-based gene expression assay and nonhuman primate model of edema to study the edemagenic properties of PPARgamma agonists" Get all the results and reference details, order at left...
2.	Weight Gain 09/01/2008 - "Oedema, weight gain and heart failure were more evident with muraglitazar" 05/01/2006 - "Weight gain and edema were more common when muraglitazar was compared with a submaximal dose of pioglitazone." 05/01/2006 - "At week 24, weight gain (1.4 and 0.6 kg, respectively) and edema (9.2 and 7.2%, respectively) were observed in the muraglitazar and pioglitazone groups; at week 50, weight gain and edema were 2.5 and 1.5 kg, respectively, and 11.8 and 8.9%, respectively" 02/01/2007 - "CONCLUSIONS AND IMPLICATIONS: Although muraglitazar has a better glucose lowering profile, it also has a greater potential for weight gain than rosiglitazone" 02/01/2007 - "Pre-adipocyte differentiation, expression of genes for adipogenesis (aP2), fatty acid oxidation (ACO) and sodium reabsorption (ENaCgamma and Na+, K+-ATPase); haemodilution parameters and serum electrolytes were measured to delineate the role of muraglitazar in causing weight gain vis a vis rosiglitazone" Get all the results and reference details, order at left...
3.	Neoplasms (Cancer) 07/01/2007 - "Considering that muraglitazar is nongenotoxic, the observed tumorigenic effects in mice and rats have no established clinical relevance since they occurred at either clinically nonrelevant exposures (gallbladder and adipose tumors) or by a species-specific mechanism (urinary bladder tumors)." 01/01/2006 - "Muraglitazar, a PPARalpha/gamma agonist, dose-dependently increased urinary bladder tumors in male Harlan Sprague-Dawley (HSD) rats administered 5, 30, or 50 mg/kg/day for up to 2 years" 09/15/2007 - "We previously reported prevention of urolithiasis and associated rat urinary bladder tumors by urine acidification (via diet acidification) in male rats treated with the dual peroxisome proliferator-activated receptor (PPAR)alpha/gamma agonist muraglitazar" Get all the results and reference details, order at left...
4.	Heart Failure 09/01/2008 - "Oedema, weight gain and heart failure were more evident with muraglitazar" 11/23/2005 - "OBJECTIVE: To evaluate the incidence of death, myocardial infarction (MI), stroke, congestive heart failure (CHF), and transient ischemic attack (TIA) in diabetic patients treated with muraglitazar compared with controls" 05/01/2006 - "At week 50, heart failure was reported in seven patients (five with muraglitazar and two with pioglitazone), and seven deaths occurred: three from sudden death, two from cerebrovascular accident, and one from pancreatic cancer in the muraglitazar group and one from perforated duodenal ulcer in the pioglitazone group" Get all the results and reference details, order at left...
5.	Urolithiasis 01/01/2006 - "Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action." 09/15/2007 - "We previously reported prevention of urolithiasis and associated rat urinary bladder tumors by urine acidification (via diet acidification) in male rats treated with the dual peroxisome proliferator-activated receptor (PPAR)alpha/gamma agonist muraglitazar" Get all the results and reference details, order at left...
23 Diseases and 15 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	PPAR alpha
2.	PPAR gamma
3.	Peroxisome Proliferator-Activated Receptors (PPAR)
4.	pioglitazone (Actos)
5.	Sodium
6.	rosiglitazone (Avandia)
7.	Ghrelin
8.	Interleukin 1 Receptor Antagonist Protein (Anakinra)
9.	Adiponectin
10.	Thiazolidinediones
86 Drugs and Important Bio-Agents and 10 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>